Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,359 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,146 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (645)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06084234 | National Liver Cancer Screening Trial(TRACER) | recruiting | Phase 4 | 5,500 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07120295 | Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories | recruiting | Phase 4 | 75 | University of Colorado, DenverOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07801027 | A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) | not yet recruiting | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 3, 2026 | clinicaltrials |
| NCT07486713 | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | recruiting | Phase 4 | 16 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07059494 | Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant | recruiting | Phase 4 | 40 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07668570 | SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma | not yet recruiting | Phase 4 | 36 | Hebei Medical University Fourth HospitalOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study | recruiting | Phase 4 | 160 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07150624 | The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine | recruiting | Phase 4 | 96 | Anhui Provincial HospitalOTHER_GOV | 1 | May 11, 2026 | clinicaltrials |
| NCT03151213 | Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver(pregabalin) | completed | Phase 4 | 70 | Sherief Abd-ElsalamOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04288323 | Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis | completed | Phase 4 | 79 | University of California, San DiegoOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT02081755 | Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer | enrolling by invitation | Phase 4 | 336 | Baylor Research InstituteOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05634720 | Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer | active not recruiting | Phase 4 | 20 | Duke UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07358975 | Prediction of Complications in Hepatic Tumors | not yet recruiting | Phase 4 | 192 | Rigshospitalet, DenmarkOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07262957 | Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)(PANENCA) | recruiting | Phase 4 | 400 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06717919 | HOPE Against Cancer Recurrence in HCC(HOPE4Cancer) | recruiting | Phase 4 | 220 | Philipp DutkowskiOTHER | 17 | Dec 16, 2025 | clinicaltrials |
| NCT03963206 | Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)(CLERANCE) | completed | Phase 4 | 110 | Hospices Civils de LyonOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07160361 | Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB | not yet recruiting | Phase 4 | 56 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT06077487 | Ketamine-assisted Therapy for Advanced GI Cancer | terminated | Phase 4 | 1 | Brian Anderson, MDOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06923176 | Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment(BRCSRRRHCCART) | not yet recruiting | Phase 4 | 704 | Zhiyun YangOTHER | 0 | Apr 11, 2025 | clinicaltrials |
| NCT05551299 | Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy(CARP) | recruiting | Phase 4 | 258 | University of LeipzigOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT05245877 | Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery(PREPOSTEROUS2) | recruiting | Phase 4 | 800 | Helsinki University Central HospitalOTHER | 3 | Feb 14, 2025 | clinicaltrials |
| NCT06594744 | Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC(P-HCC-CVL) | recruiting | Phase 4 | 120 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05848947 | SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA(MAApping) | completed | Phase 4 | 5 | Sirtex MedicalINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT03024684 | Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment(SHOT) | active not recruiting | Phase 4 | 240 | Chiayi Christian HospitalOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06464380 | Anti-cancer Potentiality of Saffron Against Hepatocellular Carcinoma | not yet recruiting | Phase 4 | 40 | Ain Shams UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06590844 | "cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma | unknown | Phase 4 | 37 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06496815 | Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy | not yet recruiting | Phase 4 | 32 | Tongji HospitalOTHER | 0 | Jul 11, 2024 | clinicaltrials |
| NCT06417606 | Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 20 | Zhiyong HuangOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT04562428 | The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial | completed | Phase 4 | 10 | China Medical University HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06398028 | The Preoperative Administration of ICG Improves Tumor Detection in Patients Undergoing Minimally Invasive Hepatic Resection Guided by Conventional Intraoperative Ultrasound. | recruiting | Phase 4 | 173 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06311916 | Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. | not yet recruiting | Phase 4 | 312 | Chen XiaopingOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT05124002 | Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 66 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06041425 | The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE | completed | Phase 4 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04297254 | A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC | completed | Phase 4 | 50 | Eisai Pharmaceuticals India Pvt. LtdINDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT04569799 | Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE(TACE) | completed | Phase 4 | 26 | Milton S. Hershey Medical CenterOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06003673 | A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC | unknown | Phase 4 | 20 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT02174575 | Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | withdrawn | Phase 4 | 0 | Tokyo Medical and Dental UniversityOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04653818 | HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial(RCT) | completed | Phase 4 | 84 | Alexandria UniversityOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05670561 | Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular Carcinoma | unknown | Phase 4 | 60 | The Second Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05416073 | Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma(TACE-HAIC) | unknown | Phase 4 | 70 | The Second Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05185505 | Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | recruiting | Phase 4 | 24 | The Methodist Hospital Research InstituteOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05331911 | Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors | recruiting | Phase 4 | 500 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05113290 | Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment | unknown | Phase 4 | 66 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT02812992 | Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients(GrantPax) | completed | Phase 4 | 32 | AIO-Studien-gGmbHOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04127396 | Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT | unknown | Phase 4 | 72 | Beijing Ditan HospitalOTHER | 1 | Jul 23, 2021 | clinicaltrials |
| NCT02472249 | Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC | completed | Phase 4 | 10 | University Health Network, TorontoOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT03007225 | Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients | completed | Phase 4 | 50 | Ain Shams UniversityOTHER | 0 | Oct 22, 2020 | clinicaltrials |
| NCT01760616 | Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy | terminated | Phase 4 | 790 | Qidong Gaitianli Medicines Co., LtdINDUSTRY | 1 | Mar 6, 2020 | clinicaltrials |
| NCT04269369 | Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients | unknown | Phase 4 | 250 | Jessa HospitalOTHER | 0 | Feb 13, 2020 | clinicaltrials |
| NCT02504983 | Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma | unknown | Phase 4 | 200 | Chang Gung Memorial HospitalOTHER | 1 | Feb 5, 2020 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials